Melanoma Clinical Trials in Detroit

Showing 101-120 of 149 trials

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

NCT00861913

This phase II trial is studying the side effects of pazopanib hydrochloride and to see how well it works in treating patients with metastatic melanoma that cannot be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Recurrent MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7

National Cancer Institute (NCI)13 participantsStarted Apr 2009

Jacksonville, Florida, United States • Detroit, Michigan, United States • Rochester, Minnesota, United States +1 more locations

COMPLETEDPHASE2< 1 mile

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

NCT01673854

The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.

Melanoma

Bristol-Myers Squibb70 participantsStarted Sep 2012

Beverly Hills, California, United States • Jacksonville, Florida, United States • Orlando, Florida, United States +11 more locations

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Melanoma Trials in Other Cities

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

CCI-779 in Treating Patients With Metastatic Melanoma

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Phase II, 2nd Line Melanoma - RAND Monotherapy

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Other Conditions in Detroit